Introduction {#s1}
============

Cancer cells require the expression of certain genes, called 'addictions' or 'genetic dependencies', that encode proteins necessary for tumor growth. Silencing the expression of these genes or blocking the activity of the proteins that they encode can trigger cell death and durable tumor regression ([@bib37]). Identifying and characterizing cancer dependencies is therefore a key goal of pre-clinical cancer research.

The Maternal Embryonic Leucine Zipper Kinase (MELK) has been implicated as a cancer dependency and putative drug target in multiple cancer types, including melanoma, colorectal cancer, and triple-negative breast cancer ([@bib7]; [@bib55]; [@bib63]; [@bib15]; [@bib14]; [@bib26]). MELK is over-expressed in these cancers, and high expression of MELK is associated with poor patient prognosis ([@bib63]; [@bib43]; [@bib42]; [@bib46]; [@bib17]). Moreover, knockdown of MELK using RNA interference (RNAi) has been reported to block cancer cell proliferation and trigger cell cycle arrest or mitotic catastrophe ([@bib55]; [@bib63]; [@bib17]; [@bib33]; [@bib35]; [@bib3]). On the basis of these pre-clinical results, several companies have developed small-molecule MELK inhibitors, and one MELK inhibitor (OTS167) is currently being tested in multiple clinical trials ([@bib40]).

In contrast to these results, we recently reported that triple-negative breast cancer cells harboring CRISPR/Cas9-induced loss-of-function mutations in MELK proliferate at wild-type levels in vitro ([@bib34]). Additionally, we demonstrated that the MELK inhibitor OTS167 remained effective against MELK-mutant cells, suggesting that OTS167 kills cells through an off-target mechanism. These results have been replicated by an independent group, who further demonstrated that the shRNA vectors commonly used to study MELK also kill cells in a MELK-independent manner ([@bib22]). The off-target effects of both the small-molecule MELK inhibitor and the MELK-targeting shRNAs provide a potential explanation for certain previous results obtained studying this reported drug target.

Despite the conflicting in vitro data, MELK expression remains one of the strongest predictors of patient mortality in diverse cancer types ([@bib53]). Additionally, MELK has been implicated in several other cancer-related processes, including cancer stem cell maintenance, chemotherapy resistance, anchorage-independent growth, and reactive oxygen species (ROS)-signaling ([@bib63]; [@bib15]; [@bib3]; [@bib32]; [@bib49]; [@bib6]; [@bib20]; [@bib21]). These processes may not be challenged by the routine in vitro growth assays that have been performed in MELK-knockout (MELK-KO) cells to date. Several previous studies were also conducted using distinct RNAi constructs and small-molecule inhibitors, raising the possibility that they reflect true functions of this kinase. Moreover, the over-expression of MELK has been reported to transform cells, suggesting that in addition to MELK's putative role as a cancer dependency, it may also function as a driver oncogene ([@bib63]).

While RNA interference is susceptible to off-target interactions that confound experimental interpretation ([@bib24], [@bib25]), CRISPR/Cas9 mutagenesis is also prone to several important limitations. In particular, clonal cell lines harboring Cas9-induced modifications must be expanded from a single cell with a mutation of interest to several million cells. This intense pressure may select for secondary mutations that blunt any anti-proliferative consequences of the original mutation ([@bib23]). In a therapeutic context, the immediate inhibition of a particular target achieved with a small-molecule drug may induce a more severe phenotype than observed in a CRISPR-modified cell line subjected to evolutionary pressure over the course of days or weeks.

To investigate the role of MELK in cancer-related processes beyond cell proliferation, and to assess the therapeutic potential of immediate MELK inhibition, we performed assays combining CRISPR-knockout cell lines with a recently described, highly specific MELK inhibitor ([@bib22]). In a variety of in vitro and in vivo challenges, we found that cells lacking MELK behave indistinguishably from wild-type cells. Moreover, through a close analysis of gene expression data, we report that MELK levels strongly correlate with mitotic activity in human tumors, suggesting that MELK expression may function as an indirect proxy for rapid cell division. In total, these results cast doubt on the possibility that MELK-specific inhibition will serve as a useful monotherapy in cancer.

Results {#s2}
=======

MELK over-expression fails to transform immortalized cell lines {#s2-1}
---------------------------------------------------------------

The over-expression of driver oncogenes allows immortalized but non-transformed cell lines to form colonies when grown in soft agar, a phenotype that is tightly linked with in vivo tumorigenicity ([@bib51]; [@bib10]; [@bib9]). It has previously been reported that the over-expression of MELK was sufficient to induce anchorage-independent growth in several cell lines, including Rat1 fibroblasts expressing dominant-negative p53 (p53dd) and the human mammary epithelial cell line MCF10A ([@bib63]). We attempted to replicate these results using Rat1-p53dd and MCF10A cells, as well as the immortalized 3T3 mouse fibroblast cell line. To accomplish this, we stably transduced each cell line with a retroviral vector encoding either the mouse or the human MELK protein. Western blot analysis confirmed that full-length mouse or human MELK was over-expressed in all six cell lines that we generated relative to the level of MELK in vector-transduced control cell lines ([Figure 1A,D](#fig1){ref-type="fig"}). Consistent with previous reports ([@bib17]; [@bib2]), we found that both ectopic and endogenous MELK were stabilized and phosphorylated in mitotic cells, suggesting that the transgenic MELK was functional ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

![MELK over-expression fails to confer anchorage-independent growth.\
(**A**) Western blot analysis of mouse MELK over-expression in 3T3, Rat1-p53dd, and MCF10a cell lines. (**B**) Quantification of colony formation of control and mouse MELK over-expressing cell lines in soft agar. For each assay, colonies were counted in at least 15 fields under a 10x objective. Boxes represent the 25th, 50th, and 75th percentiles of colonies per field, while the whiskers represent the 10th and 90th percentiles. (**C**) Representative images of the indicated cell lines grown in soft agar. (**D**) Western blot analysis of human MELK over-expression in 3T3, Rat1-p53dd, and MCF10a cell lines. (**E**) Quantification of colony formation of control and human MELK over-expressing cell lines in soft agar. For each assay, colonies were counted in at least 15 fields under a 10x objective. Boxes represent the 25th, 50th, and 75th percentiles of colonies per field, while the whiskers represent the 10th and 90th percentiles. (**F**) Representative images of the indicated cell lines grown in soft agar.](elife-32838-fig1){#fig1}

As positive controls in the anchorage-independent growth assay, we transduced each cell line with an allele of H-Ras known to function as a strong driver oncogene (H-Ras^G12V^)([@bib56]), and with an allele of EGFR that weakly transforms cells (EGFR^L858R^) ([@bib18]). We then assessed whether cell lines over-expressing each gene would proliferate when suspended in soft agar. As expected, cells that had been transduced with an empty vector exhibited minimal anchorage-independent growth, while cells transduced with H-Ras^G12V^ or EGFR^L858R^ formed numerous colonies ([Figure 1B--C and E--F](#fig1){ref-type="fig"}). However, in multiple independent experiments, we failed to detect an increase in anchorage-independent growth in any of the six cell lines over-expressing either mouse or human MELK. We conclude that, under the conditions tested, the over-expression of MELK fails to transform cells.

MELK is dispensable for growth in vitro and in vivo {#s2-2}
---------------------------------------------------

We previously showed that MELK was not required for cell division in two triple-negative breast cancer cell lines, Cal51 and MDA-MB-231 ([@bib34]). However, MELK has been reported to support growth in several other cancer types, including colorectal cancer and melanoma ([@bib14]; [@bib26]; [@bib17]; [@bib6]). To examine the role of MELK in other cancer types, we used CRISPR/Cas9 to generate multiple MELK-knockout (MELK-KO) clones in A375, a melanoma cell line, and DLD1, a colorectal cancer cell line ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As controls, we also derived clones of A375 and DLD1 harboring guide RNAs that targeted the non-essential Rosa26 locus. MELK mutagenesis was verified by sequencing the sites targeted by the gRNA, and loss of the MELK protein was verified by western blotting with two antibodies that recognize distinct epitopes ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). MELK-KO melanoma and colorectal cancer clones grew at wild-type levels in vitro, demonstrating that MELK is dispensable for proliferation in these cancer types as well ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We previously reported that OTS167, a putative MELK inhibitor in clinical trials, kills breast cancer cells in a MELK-independent manner ([@bib34]). Consistent with these observations, MELK-KO and Rosa26 clones were equally sensitive to OTS167, verifying that this drug kills cells via an off-target effect across cancer types ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

Many genes that are non-essential for cell division in vitro may still play crucial roles in cancer by supporting other processes, including stem-cell renewal, resistance to anoikis, and angiogenesis ([@bib45]; [@bib65]; [@bib39]; [@bib8]). We therefore subjected our MELK-KO and Rosa26 clones to various in vitro and in vivo assays to assess whether MELK loss impairs any cancer-related phenotypes. Although all MELK-KO cells grow well when seeded at high density in proliferation assays ([@bib34]; [@bib22]), plating cells at low density can challenge a cell's colony-forming ability and replicative lifespan ([@bib13]). To test whether MELK loss confers a defect in colony growth, MELK-KO and Rosa26 A375, Cal51, DLD1, and MDA-MB-231 clones were serially diluted and allowed to grow at varying cell densities. Crystal violet staining of these plates revealed that the loss of MELK failed to impair colony growth relative to the control Rosa26 cell lines ([Figure 2A](#fig2){ref-type="fig"}). In fact, one MELK-KO clone (MDA-MB-231 c1) grew consistently better than either control clone in this assay. Significant variation in proliferative capacity has previously been described among independent clones of the MDA-MB-231 cell line ([@bib30]) and may arise due to heterogeneity in the parental population or secondary mutations acquired during cell line derivation.

![MELK is dispensable for growth in vitro and in vivo.\
(**A**) Crystal violet staining of serial dilution plates of control and MELK knockout clones from A375 (melanoma), Cal51 (breast cancer), DLD1 (colorectal cancer), and MDA-MB-231 (breast cancer) cell lines. (**B**) Representative images of colonies of A375 control and MELK knockout clones grown in soft agar. (**C**) Quantification of colony formation in A375, DLD1, and MDA-MB-231 MELK-KO and control clones. For each assay, colonies were counted in at least 15 fields under a 10x objective. Boxes represent the 25th, 50th, and 75th percentiles of colonies per field, while the whiskers represent the 10th and 90th percentiles. (**D--E**) Representative images and quantification of mammosphere growth in Cal51 or MDA-MB-231 MELK-KO and control clones. For each assay, mammospheres were counted in at least six fields under a 10x objective. Boxes represent the 25th, 50th, and 75th percentiles of colonies per field, while the whiskers represent the 10th and 90th percentiles. (**F--G**) Representative images and quantification of xenograft growth in nude mice. Cal51 and MDA-MB-231 MELK-KO and control clones were injected subcutaneously into nude mice, and then tumor growth was measured every 3 days. Arrows indicate the location of the tumor. Error bars in the volume measurements indicate the standard error.](elife-32838-fig2){#fig2}

To further investigate the impact of MELK loss on anoikis and tumorigenicity, MELK-KO and Rosa26 cells were plated in soft agar. However, we observed no significant difference in anchorage-independent growth between MELK-KO cells and Rosa26 cells in every cell line tested ([Figure 2B--C](#fig2){ref-type="fig"}). MELK has previously been implicated in the maintenance of breast cancer stem cells ([@bib15]; [@bib20]; [@bib31]). We therefore tested whether loss of MELK impairs mammosphere formation, a phenotype tightly linked with breast cancer stem cell activity ([@bib19]). While we observed inter-clonal variability in mammosphere growth, all MELK-KO clones were capable of forming mammospheres, and two MELK-KO clones exhibited consistently greater mammosphere formation than their wild-type controls ([Figure 2D--E](#fig2){ref-type="fig"}). We conclude that MELK is dispensable for growth as a mammosphere.

Finally, we sought to determine whether MELK was required for tumor formation in vivo. To address this, we performed flank injections into nude mice with multiple clones of Cal51 and MDA-MB-231 MELK-KO and Rosa26 cells. Across all clones tested, 23 of 34 injections with MELK-KO cells and 24 of 34 injections with Rosa26 cells resulted in detectable tumor formation, and no significant growth defect was observed in any MELK-KO clone ([Figure 2F--G](#fig2){ref-type="fig"}). Consistent with our previous assays, we observed superior growth in the MDA-MB-231 MELK-KO c1 clone, while MDA-MB-231 MELK-KO c2 and Rosa26 c2 grew slowly but at equivalent rates ([Figure 2G](#fig2){ref-type="fig"}). The slow growth of MDA-MB-231 Rosa26 c1, MELK-KO c2, and Rosa26 c2 was unexpected, as MDA-MB-231 is reported to grow aggressively in vivo ([@bib44]). We hypothesized that the poor growth of many of our MDA-MB-231 clones could reflect the fact that cells in the parental population exhibit different abilities to form tumors, and by chance, we isolated several clones with limited tumor-initiating capacity ([@bib12]; [@bib5]). To further explore the role of MELK in tumorigenesis, we transduced the parental MDA-MB-231 population with guide RNAs targeting either Rosa26 or MELK, and then selected the gRNA-expressing populations without single-cell cloning. Western blot analysis verified that transduction with the MELK-targeting gRNAs ablated MELK protein expression ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). After injection into nude mice, these cell populations grew more rapidly than any clonal cell line, and the MELK-depleted cells exhibited equivalent or superior tumor growth compared to the control populations ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). In total, these results demonstrate that MELK is dispensable for the proliferation of cancer cells in vitro and in vivo.

MELK is not required for the phosphorylation or expression of previously reported targets {#s2-3}
-----------------------------------------------------------------------------------------

MELK has been reported to support cancer cell proliferation by phosphorylating various proteins involved in splicing, translation, metabolism, and cell cycle progression ([@bib49]; [@bib62]; [@bib61]; [@bib48]; [@bib27]). In particular, a recent publication reported that MELK phosphorylates eukaryotic translation initiation factor 4B (eIF4B), and this phosphorylation event promotes cell survival by increasing translation of the anti-apoptotic protein MCL1 [@bib62]). However, western blot analysis revealed normal levels of eIF4B phosphorylation in MELK-knockout A375, Cal51 and MDA-MB-231 cells ([Figure 3---figure supplement 1A--C](#fig3s1){ref-type="fig"}). Additionally, MELK-KO cell lines continued to express MCL1, the putative downstream target of eIF4B ([Figure 3---figure supplement 1D--E](#fig3s1){ref-type="fig"}). We conclude that MELK is not required for eIF4B phosphorylation or MCL1 translation.

MELK is dispensable for cell growth under exogenous stress {#s2-4}
----------------------------------------------------------

Developing tumors must survive in hypoxic and nutrient-poor conditions ([@bib59]), and MELK has been implicated in glucose signaling and in the detection of ROS ([@bib49]; [@bib29]). We therefore considered the possibility that MELK expression is necessary to support growth under metabolic or environmental stress. To generate ROS stress, we cultured cells in varying concentrations of H~2~O~2~, but we observed no difference in sensitivity between MELK-KO and control Rosa26 clones ([Figure 3A](#fig3){ref-type="fig"}). MELK has been suggested to contribute to ROS signaling by phosphorylating ASK1 (Jung et al., 2008); however, this protein remained phosphorylated at normal levels in cells lacking MELK ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). MELK-KO clones also exhibited wild-type levels of growth when cultured under hypoxic, serum-deprived, or glucose-limited conditions ([Figure 3B--D](#fig3){ref-type="fig"}). We conclude that MELK is dispensable for proliferation under common metabolic stresses.

![MELK is not required for growth under stress.\
(**A**) Dose-response curves of Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO clones grown in the presence of H~2~O~2~. (**B--D**) Crystal violet staining of A375, Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO clones grown as serial dilutions under the indicated stressful culture condition. (**E--I**) Dose-response curves of Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO clones grown in the presence of the indicated chemotherapy drug.](elife-32838-fig3){#fig3}

As high MELK expression is associated with poor patient prognosis, we wondered if MELK could promote resistance to cytotoxic chemotherapies. Indeed, it has been previously reported that knocking down or inhibiting MELK sensitizes cells to DNA damage ([@bib3]; [@bib32]; [@bib6]; [@bib31]). To test whether MELK has a role in chemotherapy resistance, we performed drug sensitivity assays in our MELK-KO and Rosa26 clones using a variety of DNA-damaging or anti-mitotic agents. However, we found that the loss of MELK failed to sensitizes cells to five common chemotherapies ([Figure 3E--I](#fig3){ref-type="fig"}). In total, these results demonstrate that MELK is dispensable for cell survival under metabolic and cytotoxic stress.

Acute inhibition of MELK fails to block proliferation {#s2-5}
-----------------------------------------------------

Deriving CRISPR-knockout clones from single cells selects for a population of cells that are capable of surviving clonal expansion. Since our MELK-KO cell lines were generated from single cells, we considered the possibility that MELK plays an important role supporting proliferation, but the clones we generated had evolved to tolerate the loss of MELK. To assess this possibility, we performed an 'epistasis' experiment combining our MELK-knockout clones with a recently described, highly-specific small molecule MELK inhibitor, HTH-01--091 ([@bib22]). We reasoned that treating Rosa26 clones with HTH-01--091 would reveal the consequences of the acute loss of MELK. However, if such phenotype(s) were also present in MELK-KO cell lines treated with HTH-01--091, then the phenotype(s) could be attributed to an off-target effect of the drug.

We first sought to identify a concentration at which HTH-01--091 inhibited MELK in our cells of interest. However, as described in this manuscript, we lacked a verified MELK substrate whose phosphorylation status could be monitored to confirm MELK inhibition. Nonetheless, it has been reported that a by-product of MELK inhibition is the degradation of MELK protein ([@bib3]; [@bib22]). Therefore, to determine an effective concentration of HTH-01--091, we monitored the level of MELK protein after drug treatment by western blot. We found that 1 µM HTH-01--091 triggered near-complete MELK degradation in Cal51, DLD1, and MDA-MB-231 cells ([Figure 4A](#fig4){ref-type="fig"}). The loss of MELK was not an indirect effect of cell cycle arrest, as these cells maintained high levels of the mitotic marker cyclin B. This concentration was therefore used in subsequent assays.

![Acute inhibition of MELK fails to block growth.\
(**A**) Western blot analysis of MELK expression levels during treatment with 1 µM HTH-01--091 in the Cal51, DLD1, and MDA-MB-231 Rosa26 clonal cell lines. (**B**) Crystal violet staining of Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO cell lines grown as serial dilutions in the presence of DMSO or 1 µM HTH-01--091. (**C**) Quantification and representative images of colony formation of DLD1 and MDA-MB-231 Rosa26 and MELK-KO clones in soft agar in the presence of DMSO or 1 µM HTH-01--091. (**D**) Dose-response curves of Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO clones grown in the presence of HTH-01--091. (**E**) Dose-response curves of Cal51, DLD1, and MDA-MB-231 Rosa26 and MELK-KO clones grown in the presence of 1 µm HTH-01--091 and the indicated chemotherapy drug.](elife-32838-fig4){#fig4}

To test whether the acute inhibition of MELK affected clonogenicity or anchorage-independent growth, we grew MELK-KO and Rosa26 cells on plastic or in soft agar in the presence of DMSO or 1 µM HTH-01--091. Neither MELK-KO nor Rosa26 clones were affected by HTH-01--091 treatment, verifying that MELK is dispensable for colony formation and anchorage-independent growth in these cells ([Figure 4B--C](#fig4){ref-type="fig"}). Indeed, a drug sensitivity assay revealed that HTH-01--091 exhibited significant anti-proliferative effects only at concentrations above \~5 µM ([Figure 4D](#fig4){ref-type="fig"}). This toxicity is likely a consequence of an off-target effect, as these drug concentrations were found to affect Rosa26 and MELK-KO cells equivalently.

We next sought to test whether acute MELK inhibition sensitized cells to chemotherapy. To accomplish this, we treated MELK-KO and Rosa26 clones with various chemotherapy drugs in the presence of HTH-01--091. Consistent with our previous results, HTH-01--091 treatment failed to sensitize the Rosa26 clones to 5-florouracil or paclitaxel treatment ([Figure 4E](#fig4){ref-type="fig"}). Finally, we assessed the effect of HTH-01--091 treatment on eIF4B phosphorylation and MCL1 expression, and found that MELK inhibition failed to affect either target ([Figure 3---figure supplement 1G--H](#fig3s1){ref-type="fig"}). In total, these results demonstrate that the acute loss of MELK results in no significant defect in cell viability, proliferation, or drug resistance and suggest that our knockout clones have not acquired mutations that tolerize cells to the loss of MELK.

The association between MELK expression and cancer lethality is due to its correlation with mitotic activity {#s2-6}
------------------------------------------------------------------------------------------------------------

Our in vitro and in vivo experiments failed to reveal any cancer-related phenotypes affected by either the deletion or over-expression of MELK. Yet, MELK is up-regulated in many cancer types ([@bib17]), and high levels of MELK expression have been reported to confer a dismal clinical prognosis ([@bib63]; [@bib43]; [@bib42]; [@bib46]). If MELK plays no overt role in cancer biology, then why would MELK expression be linked with death from cancer? We note that MELK expression is cell cycle-regulated, peaking in mitosis ([@bib63]; [@bib2]), and gene signatures that capture mitotic activity have been found to be prognostic in multiple cancer types ([@bib53]; [@bib60]; [@bib16]). We therefore considered the possibility that, rather than functioning as an oncogene or a cancer dependency, MELK expression could report cell division within a tumor. To assess the link between MELK expression and cell division, we analyzed gene expression data from different sets of cells and tissues. In normal human tissue, *MELK* transcript expression was the lowest in non-proliferative organs, including the heart and skeletal muscle, while *MELK* expression was the highest in organs with on-going mitotic activity, including the bone marrow and testes ([Figure 5A](#fig5){ref-type="fig"}). Indeed, across 32 tissue types, *MELK* levels were highly correlated with the expression of the proliferation marker *MKI67* (R = 0.93). Similarly, in human fibroblasts cultured until senescence, *MELK* expression decreased up to 11-fold between proliferating and arrested populations, while stimulating lymphocytes to divide increased *MELK* expression 20-fold ([Figure 5B--C](#fig5){ref-type="fig"}). These data suggest that *MELK* levels reflect mitotic activity in diverse cell types.

![*MELK* expression correlates with proliferation markers in vitro, in normal tissue, and in cancer.\
(**A**) A heatmap of the expression of either *MKI67* or *MELK* in normal tissue sorted according to *MKI67* expression ([@bib58]). (**B**) The expression level of either *MKI67* or *MELK* is displayed in five different primary human fibroblast lines at either low passage (proliferating) or high passage (senescence) ([@bib38]). (**C**) The expression level of either *MKI67* or *MELK* is displayed in CD4 + lymphocytes resting or after stimulation with α-CD3/α-CD28 beads ([@bib1]). (**D**) The expression level of *MELK* is plotted against the expression of five common proliferation markers in cohorts of patients with breast cancer, glioma, or melanoma ([@bib47]; [@bib57]; [@bib28]). Black lines represent linear regressions plotted against the data. (**E**) Univariate Cox proportional hazards models were calculated for the 15 breast cancer cohorts listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. For each cohort, the expression of either *MELK* or the average expression of *CCNB1, MCM2, MKI67, PCNA,* and *TOP2A* in each tumor was regressed against patient outcome. Dotted lines represent Z scores of 1.96, corresponding to a p-value of 0.05. The black line represents a linear regressions plotted against the data. (**F**) Bar graphs depict the number of cohorts in which *MELK* and a proliferation meta-gene are significantly associated with poor outcome in either univariate or bivariate models. The full results are presented in [Supplementary file 3](#supp3){ref-type="supplementary-material"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}. (**G**) Kaplan-Meier curves displaying disease-specific survival in one breast cancer cohort ([@bib41]). Patients were split into two populations based on the average expression of either *MELK* or the five-gene proliferation meta-gene.](elife-32838-fig5){#fig5}

To examine the link between MELK and cell division in cancer, we compared the levels of *MELK* expression with five well-characterized proliferation markers: *MKI67, PCNA, CCNB1, MCM2,* and *TOP2A* ([@bib64]). In cohorts of patients with tumor types in which MELK levels have previously been associated with advanced disease, *MELK* expression was significantly correlated with each of the proliferation genes (median correlation = 0.82; [Figure 5D](#fig5){ref-type="fig"}). We then sought to determine whether the correlation between *MELK* expression and proliferation could explain the prognostic significance of MELK. To test this, we collected 15 breast cancer microarray datasets from patients with known clinical outcomes. For each patient cohort, we calculated Z scores from univariate Cox proportional hazards models, which assess the significance of a putative prognostic variable. A Z score greater than 1.96 indicates that increasing expression of a gene is associated with dismal prognosis at a p\<0.05 threshold ([@bib16]). We found that *MELK* expression was significantly linked with poor outcome in 14 of 15 datasets ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Similarly, a proliferation meta-gene derived by averaging the normalized expression of *MKI67, PCNA, CCNB1, MCM2,* and *TOP2A* was significantly associated with poor outcome in 13 of 15 datasets ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Strikingly, we found that the Z scores generated by our univariate proliferation models were significantly correlated with the Z scores generated by the univariate *MELK* models: in patient cohorts in which proliferation was highly-prognostic, *MELK* expression was also highly-prognostic, and vice-versa ([Figure 5E](#fig5){ref-type="fig"}; R = 0.78, p\<0.001). These analyses suggested that *MELK* expression and cell proliferation capture very similar clinical information. To test whether *MELK* expression remained prognostic when controlling for mitotic activity, we generated bivariate Cox models that included both *MELK* expression and the proliferation meta-gene ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). In the bivariate models, *MELK* was significantly associated with patient outcome in only 2 of 15 datasets, demonstrating that considering tumor cell proliferation ablated *MELK*'s clinical utility ([Figure 5F](#fig5){ref-type="fig"}). Thus, when tumors are stratified according to their proliferation level, *MELK* expression is no longer prognostic ([Figure 5G](#fig5){ref-type="fig"}). In total, these results suggest that the observed pattern of *MELK* expression in cancer can be explained by the fact that *MELK* is up-regulated in mitotic cells.

Discussion {#s3}
==========

Pre-clinical cancer research efforts apply different genetic and chemical tools (RNA interference, CRISPR, and small-molecule inhibitors) to a variety of artificial assays (in vitro proliferation, xenograft growth, etc.) in order to discover targets that will have clinical efficacy when inhibited in human patients. No single assay perfectly mimics the behavior of a tumor in a human cancer patient, and no single chemical or genetic tool exhibits absolute specificity. Nonetheless, we believe that by using multiple orthogonal approaches and assays, we can gain insight into the role that certain genes play in human malignancies. In this current manuscript, we report that combining CRISPR and a small-molecule inhibitor in a variety of assays failed to reveal a role for MELK in several cancer-related processes. These results suggest that anti-MELK monotherapies are unlikely to be effective cancer treatments.

Our previous work demonstrated that MELK is dispensable for the proliferation of triple-negative breast cancer cells in vitro ([@bib34]). Nonetheless, multiple cellular functions are dispensable for in vitro proliferation but required for tumor progression, including stem cell renewal, oxygen sensing, and chemotherapy resistance ([@bib45]; [@bib65]; [@bib39]; [@bib8]). Although MELK has been implicated in each of these processes, our results demonstrate that MELK-knockout cancer cell lines grow at wild-type levels in a variety of assays designed to test these pathways. We speculate that, as has previously been reported for one MELK inhibitor and one set of MELK-targeting shRNA's ([@bib22]), several previous studies of MELK function may have been compromised by off-target activity of the constructs and inhibitors that were used.

To assess MELK function in cancer, we used CRISPR/Cas9 to generate mutations in MELK in four different cancer cell lines. Of note, we observed variability between clones from the same parental cell line, and between clonal lines and the parental cell populations. These observations underscore the importance of assessing multiple independent clones and cell populations in CRISPR experiments. Furthermore, to rule out the possibility that our MELK-KO clones had evolved to tolerate the loss of MELK, we performed 'epistasis' experiments by treating these knockout clones with a MELK inhibitor. We reasoned that specific consequences of MELK inhibition would be detectable upon drug treatment in MELK-WT but not MELK-KO clones, while non-specific consequences of drug treatment would affect both genotypes equally. In all experiments conducted thus far, no phenotypes have been observed only in MELK-WT cells after HTH-01--091 treatment, further verifying that MELK is dispensable for cancer cell growth. We suggest that these 'epistasis' experiments can be widely applied to assess the on-target consequences of acutely inhibiting potential cancer drug targets.

Initial interest in blocking MELK function in cancer stemmed from the discovery that it was over-expressed across cancer types ([@bib17]). Further research revealed that patients whose tumors expressed the highest levels of MELK had the worst clinical outcomes ([@bib63]; [@bib43]; [@bib42]; [@bib46]; [@bib33]). As we observed no role for MELK as either an oncogene or a cancer dependency, we sought to instead investigate whether its cell cycle-dependent expression pattern could explain its prognostic value. Consistent with this hypothesis, we discovered that *MELK* transcript expression closely mirrors tumor mitotic activity. As actively-growing cancers appear to up-regulate thousands of genes involved in cell cycle progression when compared to quiescent normal tissue ([@bib64]), this observation may explain why MELK is commonly over-expressed in different malignancies. Moreover, rapid cell division in tumors is indicative of tissue de-differentiation and aggressive disease; therefore, most cell cycle-regulated genes are also associated with poor clinical outcome ([@bib53]; [@bib60]; [@bib16]). We further demonstrated that controlling for cell proliferation ablates the prognostic significance of MELK expression, suggesting that this link may explain its connection with outcome in cancer.

While many cell cycle genes are indeed suitable cancer drug targets (e.g. CDK4 and CDK6), other genes may be up-regulated during normal cell division but dispensable for this process ([@bib60]). We suggest that MELK is an example of the latter. We believe that, if MELK does play a role in cancer, it may be detectable only in very limited circumstances, and likely in vivo. As MELK-knockout mice display no observable deficiencies, MELK's function may be redundant with other kinases ([@bib63]). Future synthetic lethal screening and additional in vivo assays may clarify what role, if any, MELK plays in cancer biology.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                   Designation                                                                              Source or reference                        Identifiers                                                  Additional information
  or resource                                                                                                                                                                                                                                
  ----------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------------------------
  Cell line (human)                         A375                                                                                     ATCC                                       RRID:[CVCL_0132](https://scicrunch.org/resolver/CVCL_0132)   

  Cell line (human)                         Cal51                                                                                    Dr. David Solomon and\                     RRID:[CVCL_1110](https://scicrunch.org/resolver/CVCL_1110)   
                                                                                                                                     Dr. Todd Waldman                                                                                        

  Cell line (human)                         DLD1                                                                                     ATCC                                       RRID:[CVCL_0248](https://scicrunch.org/resolver/CVCL_0248)   

  Cell line (human)                         MDA-MB-231                                                                               ATCC                                       RRID:[CVCL_0062](https://scicrunch.org/resolver/CVCL_0062)   

  Cell line (rat)                           Rat1                                                                                     CSHL Cell Line Repository                  RRID:[CVCL_0512](https://scicrunch.org/resolver/CVCL_0512)   

  Cell line (human)                         MCF10A                                                                                   Dr. Camila Dos Santos                      RRID:[CVCL_0598](https://scicrunch.org/resolver/CVCL_0598)   

  Cell line (mouse)                         3T3                                                                                      CSHL Cell Line Repository                  RRID:[CVCL_0594](https://scicrunch.org/resolver/CVCL_0594)   

  Cell line (human)                         All MELK-knockout and Rosa26 control clonal cell lines (A375, Cal51, DLD1, MDA-MB-231)   This paper and\                                                                                         These cell lines were derived in this paper. Available from Dr. Jason Sheltzer.
                                                                                                                                     Lin et al., (eLife 2017)                                                                                

  Transfected construct                     LRG 2.1 vector                                                                           Dr. Christopher Vakoc and Dr. Junwei Shi                                                                

  Transfected construct (human and mouse)   MELK over expression plasmid                                                             Vectorbuilder,\                                                                                         
                                                                                                                                     Cyagen Corporation                                                                                      

  Antibody                                  Anti-MELK N terminal Antibody                                                            Abcam                                      ab108529                                                     1:3000 in 5% Milk TBST

  Antibody                                  Anti-MELK C terminal Antibody                                                            Cell Signal                                2274S                                                        1:10000 in 10% BSA TBST

  Antibody                                  Anti-ASK1                                                                                Abcam                                      ab45178                                                      1:1000 in 5% Milk TBST

  Antibody                                  Anti-eIF4B                                                                               Cell Signal                                3592                                                         1:2000 in 5% Milk TBST

  Antibody                                  Anti-cyclin B                                                                            Abcam                                      ab32053                                                      1:10000 in 5% Milk TBST

  Antibody                                  Anti-Phospho-ASK1                                                                        Cell Signal                                3765                                                         1:1000 in 5% BSA TBST

  Antibody                                  Anti-Phospho-eIF4B                                                                       Cell Signal                                5399                                                         1:1000 in 5% BSA TBST

  Antibody                                  Anti-MCL1                                                                                Cell Signal                                5453                                                         1:2000 in 5% Milk TBST

  Antibody                                  Anti-Alpha-Tubulin                                                                       Sigma-Aldrich                              T6199                                                        1:20000 in 5% Milk TBST

  Antibody                                  Anti-GAPDH                                                                               Santa Cruz Biotechnology                   sc-365062                                                    1:20000 in 5% Milk TBST

  Antibody                                  Anti-Rabbit                                                                              Abcam                                      ab6721                                                       1:50000 to 1:20000 in 5% Milk TBST

  Antibody                                  Anti-Mouse                                                                               Bio-Rad                                    1706516                                                      1:50000 in 5% Milk TBST

  Chemical compound,drug                    HTH-01--091                                                                              Dr. Nathanael\                                                                                          
                                                                                                                                     Gray DOI: 10.7554                                                                                       

  Chemical compound,drug                    OTSSP167                                                                                 MedChem Express                            HY-15512A                                                    

  Software, algorithm                       Survival Analysis                                                                        This paper                                                                                              <https://github.com/joan-smith/survival-analysis-scripts>
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and culture conditions {#s4-1}
---------------------------------

The identity of each human cell line was verified by STR profiling (University of Arizona Genetics Core). A375 (RRID:[CVCL_0132](https://scicrunch.org/resolver/CVCL_0132)), Cal51 (RRID:[CVCL_1110](https://scicrunch.org/resolver/CVCL_1110)), DLD1 (RRID:[CVCL_0248](https://scicrunch.org/resolver/CVCL_0248)), MDA-MB-231 (RRID:[CVCL_0062](https://scicrunch.org/resolver/CVCL_0062)) cell lines were grown in DMEM supplemented with 10% FBS, 2 mM glutamine, and 100 U/mL penicillin and streptomycin. Rat1 (RRID:[CVCL_0512](https://scicrunch.org/resolver/CVCL_0512)) cells were grown in DMEM supplemented with 5% FBS, 2 mM glutamine, and 100 U/mL penicillin and streptomycin. 3T3 (RRID:[CVCL_0594](https://scicrunch.org/resolver/CVCL_0594)) cells were grown in DMEM supplemented with 10% bovine calf serum (BCS), 2 mM glutamine, and 100 U/mL penicillin and streptomycin. MCF10A (RRID:[CVCL_0598](https://scicrunch.org/resolver/CVCL_0598)) cells were grown in Mammary Epithelial Cell Growth Medium (Lonza, Switzerland; Cat. No. CC-3150) supplemented with 5% horse serum, 100 ng/mL of cholera toxin (Sigma-Aldrich, St. Louis, MO; Cat. No. C8052) and 100 U/mL penicillin and streptomycin. All cell lines were grown in a humidified environment at 37˚C and 5% CO~2~.

Retroviral plasmid over-expression {#s4-2}
----------------------------------

Mouse and human MELK cDNA was cloned into an MMLV vector and verified by sequencing (Vectorbuilder, Cyagen Corporation). Positive and negative control plasmids were acquired from Addgene: pBabe-Puro (Addgene; Cat. No. 1764), EGFR^L858R^ (Addgene; Cat. No. 11012), and Ras^G12V^ (Addgene; Cat. No. 1768). Retrovirus was generated by transfecting plasmids into Plat-A cells (Cell BioLabs, San Diego, CA; Cat. No. RV-102) using the calcium-phosphate method ([@bib52]). Virus was harvested 48--72 hr post transfection, filtered through a 0.45 μm syringe and applied to cells with 4 μg/mL polybrene. After 24 hr, the media was changed and cells were allowed to recover in fresh media for 2 days. Subsequently, the cells were split and the appropriate antibiotic was added to select for transduced cells.

Soft agar assays {#s4-3}
----------------

To assay anchorage-independent growth, all cell lines except MCF10A were suspended at a cell count of 10,000 cells in a 0.35% Difco Agar Noble (VWR Scientific, USA; Cat. No. 90000--772) solution in a six-well plate. MCF10A cell lines were suspended at a cell count of 20,000 cells. The mixture was plated over a 0.5% Difco Agar Noble solution. Plates were allowed to solidify at room temperature for 1 hr and then placed in a 37˚C incubator overnight. 1 mL of normal growth media was added to each well the next day and every 3 days after ([@bib4]). After 14 days, colony formation was quantified under 20x magnification.

Stress assays {#s4-4}
-------------

To study the role of MELK in surviving stressful culture conditions, 30,000 MELK-KO and Rosa26 cells from DLD1 and MDA-MB-231 cell lines and 10,000 MELK-KO and Rosa26 cells from A375 and Cal51 cell lines were plated in the first column of a 24-well plate (Corning, USA; Cat. No. 3526) and then five three-fold dilution were performed across the plate. For the low-glucose conditions, low-glucose DMEM (Thermo Fisher Scientific, Waltham, MA; Cat. No. 11885076) supplemented with 10% FBS, 2 mM glutamine, and 100 U/mL penicillin and streptomycin was added to the cells. For the low serum conditions, Cal51, DLD1, and MDA-MB-231 cell lines were cultured in DMEM supplemented with 1% FBS, 2 mM glutamine, and 100 U/mL penicillin and streptomycin, while the A375 cell line was cultured in 5% FBS, 2 mM glutamine, and 100 U/mL penicillin and streptomycin. For the hypoxic conditions, cells were cultured in normal media and then placed in a hypoxic incubator set at 37°C with 2% oxygen. After 10--14 days, cells were fixed with 100% methanol and stained with 0.5% crystal violet dissolved in 25% methanol.

Mammosphere formation assay {#s4-5}
---------------------------

Mammosphere formation media was prepared using DMEM/F12 (Lonza; Cat. No. CC-3151) supplemented with 2 mM L-glutamine, 100 U/mL penicillin and streptomycin, 20 ng/mL recombinant human epidermal growth factor (Sigma Aldrich; Cat. No. E9644), 10 ng/mL recombinant human basic fibroblast growth factor (R and D Systems; 233-FB-025) and 1x B27 supplement (Invitrogen, Waltham, MA; Cat. No. 17504--044) ([@bib36]). Cells were plated at a density of 20,000 cells or 30,000 cells per well for the MDA-MB-231 and Cal51 cell lines respectively in a 6-well low attachment plate (Corning; Cat. No. CLS3814) with 3 mL of media. Fresh media was added to the wells every 3 days over the course of the assay. Mammospheres were measured 4 weeks post plating for the MDA-MB-231 cell lines and 2 weeks post plating for Cal51 cell lines.

Drug sensitivity assays {#s4-6}
-----------------------

To quantify a cell line's sensitivity to a particular drug, 10,000 A375, DLD1, or MDA-MB-231 cells or 5000 Cal51 cells were plated in 100 µL of media in an 8 × 3 matrix on a flat-bottomed 96-well plate (Corning; Cat. No. 3596). Cells were allowed 24 hr to attach, then fresh media was added to each well. The highest concentration of a drug was added onto the first row of cells and then six three-fold serial dilutions were performed. Cells were grown in the presence of the drug for 72 hr then trypsinized and counted using a MacsQuant Analyzer 10 (Milltenyi Biotec, Germany). Replicate wells were averaged and then normalized to the cell count in the untreated wells. Normalized values were plotted in Prism 7 (Graphpad, San Diego, California) and fit to a curve using a four-parameter inhibition vs. concentration model. HTH-01--091 was a kind gift of Hubert Huang and Nathanael Gray (Dana-Farber Institute). OTSSP167 was obtained from MedChem Express (Monmouth Junction, NJ; Cat. No. HY-15512A). Idarubicin, Oxaliplatin, Paciltacxel and Bleomycin were obtained from Selleck Chemicals (Houston, TX; Cat. No. S1228, S1224, S1150, and S1214). Fluorouracil was obtained from Sigma Aldrich (Cat. No. F6627-1G).

Western blot analysis {#s4-7}
---------------------

Whole cell lysates were harvested using RIPA buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X 100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, protease inhibitor cocktail, and phosphatase inhibitor cocktail). Protein concentration was quantified using the RC DC Protein Assay (Bio-Rad, Hercules, CA; Cat. No. 500--0119) or the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific; Cat. No. 23225). Equal amounts of lysate were denatured and loaded onto an 8% SDS-PAGE gel. The protein was transferred onto a polyvinylidene difluoride membrane using the Trans-Blot Turbo Transfer System (Bio-Rad). Westerns with phospho-antibodies were blocked in 5% BSA, westerns with Anti-MELK C-Terminal (Cell Signal, Danvers, MA; Cat. No. 2274S) were blocked in 10% BSA, and all other antibodies were blocked with 5% milk. The following antibodies and dilutions were used: Anti-MELK N-Terminal (Abcam, Cambridge, MA; Cat. No. ab108529) at a dilution of 1:3000, Anti-MELK C-Terminal (Cell Signal; Cat. No. 2274S) at a dilution of 1:10000, Anti-elF4B (Cell Signal; Cat. No. 3592) at a dilution of 1:2000, Anti-ASK1 (Abcam, Cat. No. ab45178) at a dilution of 1:1000, Anti-cyclin B (Abcam; Cat. No. ab32053) at a dilution of 1:10000, Anti-Phospho-ASK1 (Cell Signal; 3765) at a dilution of 1:1000, Anti-Phospho-elF4B (Cell Signal; Cat. No. 5399) at a dilution of 1:1000, and Anti-MCL1 (Cell Signal; Cat. No. 5453) at a dilution of 1:2000. Blots were incubated with the primary antibody overnight at 4°C. Anti-alpha tubulin (Sigma-Aldrich; Cat. No. T6199) at a dilution of 1:20,000 or Anti-GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA; Cat. No. sc-365062) at a dilution of 1:20,000 were used as loading controls. Membranes were washed at room temperature for an hour before they were incubated in secondary antibodies \[Anti-Rabbit (Abcam; Cat. No. ab6721) at 1:50,000 for Anti-MELK and at 1:20,000 for all other antibodies or anti-mouse (Bio-Rad; Cat. No. 1706516) at 1:50,000 for Anti-tubulin and Anti-GAPDH)\] for an hour.

Xenograft growth assays {#s4-8}
-----------------------

Nude mice were obtained from The Jackson Laboratory (Bar Harbor, ME; Cat. No. 002019). To perform the xenograft injections, breast cancer cells were harvested and resuspended at a concentration of 10^8^ cells/mL in 1X cold PBS. The cell suspension was then mixed 1:1 with growth factor reduced-matrigel (Corning; Cat. No. 47743--720). Each mouse was injected subcutaneously in the left and right flanks with 100 µL of the cell suspension, containing 5 × 10^6^ cells. Tumors were monitored by visual inspection routinely after injection. Once a tumor was visible, mice were measured every 3 days by caliper in duplicate. Tumor volume was calculated using the formula V = ½ (longer axis)(shorter axis)^2^. All mouse protocols were approved by the CSHL Institutional Animal Care and Use Committee.

CRISPR plasmid construction and virus generation {#s4-9}
------------------------------------------------

Guide RNAs were previously described in Lin et al. ([@bib34]). In short, oligonucleotides were cloned into the LRG 2.1 vector \[a gift from Junwei Shi (University of Pennsylvania) and Chris Vakoc (Cold Spring Harbor Laboratory)\] using a BsmBI digestion ([@bib50]). To produce virus, HEK293T cells were transfected using the calcium-phosphate method ([@bib52]). Supernatant was harvested 48 to 72 hr post-transfection, filtered through a 0.45-μm syringe, and then applied to cells with 4 μg/mL polybrene ([@bib52]). Guide RNAs used to disrupt MELK are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Analysis of CRISPR-mediated mutagenesis {#s4-10}
---------------------------------------

Single cells isolated via fluorescence-activated cell sorting (FACS) were grown into clonal populations. Genomic DNA was extracted from these populations with the QIAmp DNA Mini kit (Qiagen Germantown, MD; Cat. No. 51304). The cut site regions targeted by the guide RNAs were amplified using the primers listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. PCR products were then sequenced with the forward and reverse primer at the Cold Spring Harbor Laboratory sequencing facility to yield the 'Cut-site PCR' sequences shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. To analyze individual alleles, PCR products were ligated into the pCR4-TOPO TA vector from the TOPO TA Cloning Kit (Thermo Fisher Scientific; Cat. No. 450030). Ligated plasmids were transformed into One Shot Stbl3*E. coli* (Thermo Fisher Scientific: Cat. No. C737303). Plasmids from 8 to 20 colonies were extracted using QIAprep Spin Miniprep Kit (Qiagen; Cat. No. 27104) and sequenced with the forward and reverse primer at the Cold Spring Harbor Laboratory sequencing facility.

Analysis of published gene expression data {#s4-11}
------------------------------------------

Data from normal human tissues were acquired from ([@bib58]). Data from senescent fibroblasts were acquired from ([@bib38]). Data from stimulated lymphocytes were acquired from ([@bib1]). Cancer patient cohorts and probeset definitions were downloaded from the Gene Expression Omnibus as described in [Supplementary file 3](#supp3){ref-type="supplementary-material"} ([@bib11]). Data were cleaned and processed using python's pandas library to exclude missing values and to associate clinical outcomes with expression data. To generate the proliferation meta-gene, the expression of five proliferation-related genes (*MKI67, PCNA, CCNB1, TOP2A,* and *MCM2*) were collapsed by averaging. Cox proportional hazard models were constructed using the survival library in R and the coxph function as described in ([@bib53]). The Cox proportional hazard models for both univariate and bivariate analyses were run from a python script that used rpy2 to run R code from python. Source code is available on github (<https://github.com/joan-smith/survival-analysis-scripts>; a copy is archived at [https://github.com/elifesciences-publications/survival-analysis-scripts](https://github.com/elifesciences-publications))([@bib54]).
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###### MELK gRNA sequences.

Cancer cells lines used in this study and the guide RNAs that they express are displayed.

10.7554/eLife.32838.012

###### PCR primers to amplify MELK gRNA cut sites.

The sequences of all PCR primers used in this study are displayed.

10.7554/eLife.32838.013

###### Univariate Cox proportional hazards models of breast cancer outcome and the expression of a proliferation meta-gene or of *MELK*.

Cox proportional hazards survival analysis was performed on 15 breast cancer microarray datasets correlating the length of patient survival with either MELK expression or with a proliferation meta-gene comprising *MKI67, PCNA, CCNB1, MCM2,* and *TOP2A*.

10.7554/eLife.32838.014

###### Bivariate Cox proportional hazards models of breast cancer outcome and the expression of a proliferation meta-gene and of *MELK*.

Cox proportional hazards survival analysis was performed on 15 breast cancer microarray datasets correlating the length of patient survival with both MELK expression and with a proliferation meta-gene comprising *MKI67, PCNA, CCNB1, MCM2,* and *TOP2A*.

10.7554/eLife.32838.015

Major datasets {#s7}
--------------

The following previously published datasets were used:

Schmidt MBöhm Dvon Törne CSteiner EPuhl APilch HLehr HHengstler JGKölbl HGehrmann M2008The humoral immune system has a key prognostic impact in node-negative breast cancer<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11121>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE11121)

Pawitan YBjohle JAmler LBorg AEgyhazi SHall PHan XHolmberg LHuang FKlaar SLiu ETMiller LDNordgren HPloner ASandelin KShaw PMSmeds JSkoog LWedren SBergh J2005Gene expression of breast cancer tissue in a large population-based cohort of Swedish patients<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1456>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE1456)

Symmans WFSotiriou CAndre FRegitnig PDaxenbichler GHatzis C2010Endocrine Sensitivity Index Validation Dataset<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17705>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE17705)

Wang YKlijn JGZhang YSieuwerts AM2005Breast cancer relapse free survival<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2034>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE2034)

Buffa FMWinchester L2011Gene expression profiling of early primary breast cancer to identify prognostic markers and associated pathways<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22219>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE22219)

Greco DHeikkilä PBlomqvist CNevalinna H2011183 breast tumors from the Helsinki Univerisity Central Hospital with survival information<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE24450>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE24450)

Symmans WFEsserman LVidaurre T2011Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25055>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE25055)

Symmans WFHolmes FVidaurre TMartin MSouchon E Citation(s)2011Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25065>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE25065)

Nevins JR2005Breast Cancer Dataset<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3143>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE3143)

Sabatier RFinetti PAdelaïde JGuille ALane LBirnbaum DChaffanet MBertucci F2011Down-regulation of ECRG4, a candidate tumor suppressor gene in human breast cancer<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31448>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE31448)

Miller LDSmeds JGeorge JVega VBVergara LPloner APawitan YHall PKlaar SLiu ETBergh J2005An expression signature for p53 in breast cancer predicts mutation status, transcriptional effects, and patient survival<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3494>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE3494)

Wang DYLeong WL2014Internal validation cohort of breast cancers for development of ClinicoMolecular Triad Classification<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45725>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE45725)

Ivshina AVGeorge JSenko OMow BPutti TCSmeds JLindahl TPawitan YHall PNordgren HWong JELiu ETBergh JKuznetsov VAMiller LD2006Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4922>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE4922)

Loi SHaibe-Kains BDesmedt CLallemand FTutt AMGillet CEllis PHarris ABergh JFoekens JAKlijn JGLarsimont DBuyse MBontempi GDelorenzi MPiccart MJSotiriou C2007Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6532>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE6532)

Desmedt CPiette FLoi SWang YLallemand FHaibe-Kains BViale GDelorenzi MZhang YSaghatchian MBergh JLidereau REllis PHarris AKlijn JGFoekens JACardoso FPiccart MJBuyse MSotiriou C2007Strong Time Dependence of the 76-Gene Prognostic Signature<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE7390>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE7390)

Marthandan SKlement KPriebe SGroth MPlatzer MHemmerich PDiekmann S2016RNA-seq of human fibroblasts during replicative senescence<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63577>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE63577)

Uhlén MFagerberg LHallström BMLindskog COksvold PMardinoglu ASivertsson ÅKampf CSjöstedt EAsplund AOlsson IEdlund KLundberg ENavani SSzigyarto CAOdeberg JDjureinovic DTakanen JOHober SAlm TEdqvist PHBerling HTegel HMulder JRockberg JNilsson PSchwenk JMHamsten Mvon Feilitzen KForsberg MPersson LJohansson FZwahlen Mvon Heijne GNielsen JPontén F2015RNA-seq of coding RNA from tissue samples of 122 human individuals representing 32 different tissues<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2836/>Publicly available at the ArrayExpress (accession no: E-MTAB-2836)

Turcan SRohle DGoenka AWalsh LA2012IDH1 Mutation is a Master Regulator of Epigenomic Remodeling and is Sufficient to Establish the Glioma Hypermethylator Phenotype<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30339>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE30339)

Abbas ARBaldwin DMa YOuyang WGurney AMartin FFong Svan Lookeren Campagne MGodowski PWilliams PMChan ACClark HF2010Expression profiles from a variety of resting and activated human immune cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22886>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE22886)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Charles Sawyers as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Tony Hunter (Reviewer \#1); David Stokoe (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors have extended their analysis of the role of the MELK protein kinase in breast cancer cells. In their 2016 *eLife* paper, they re-examined the role of the MELK kinase, a mitotic kinase reported to be essential for basal breast carcinoma cell proliferation and be the target of OTS167, a small molecule MELK kinase inhibitor, in basal breast carcinoma (BBC). They found that CRISPR/Cas9-generated MELK knockout clones of two different TNBC breast cancer lines exhibited WT cell levels of proliferation, survival and anchorage independent growth and that MELK knockout cells remained sensitive to OTS167. They concluded that MELK is not required for TNBC cell proliferation and that OTS167 blocks growth in a MELK independent manner.

In this new study, they showed that stable overexpression of MELK in 3T3, Rat1-p53dd, and MCF10A cells did not promote colony growth or induce growth in soft agar. They also showed that colony formation and growth in soft agar of MELK-null clones of DLD1 (colorectal cancer), A375 (melanoma), Cal51 (breast cancer) and MDA-MB-231 (breast cancer) cells was similar to that of cells in which the Rosa26 locus had been targeted as a control; for Cal51 and MDA-MB-231 they showed that the MELK-null clones formed mammospheres as efficiently control cells. In addition, they found that the Cal51 and MDA-MB-231 MELK-null cells grew as well as Rosa26 control cells as flank xenografts in nude mice. Moreover, the MELK-null Cal51 and MDA-MB-231 cells were equally sensitive/resistant to H2O2, paclitaxel, idarubicin, bleomycin, oxaliplatin, and fluorouracil treatment, as their control counterparts. They also showed that acute inhibition of MELK in WT Cal51 and MDA-MB-231 cells or their MELK knockout derivatives with the highly-specific HTH-01-091MELK inhibitor caused no defect in proliferation. Finally, they re-analyzed publicly available data for a correlation between MELK expression and prognosis for breast cancer patients, and came to the conclusion that MELK expression is simply a marker for mitotic cells, and would therefore be expected to correlate with poor prognosis. These new data provide further evidence that the MELK kinase is not required for the tumorigenic properties of a variety of human cancer cell lines, including, at least for Cal51 cells, tumorigenesis.

Overall, this is a well-designed and executed study that confirms the previous data from this group and the Gray group showing that the multiple previous reports of MELK requirement in tumor cells were likely plagued by off-target effects of RNAi and small molecule reagents. This is therefore a useful addition to the small body of literature supporting this conclusion that can balance the \>30 papers proposing a MELK requirement.

Essential revisions:

1\) Although the Cal51 xenograft data are reasonable, the MDA-MB-231 xenograft data in [Figure 2G](#fig2){ref-type="fig"} are simply not convincing The Rosa 26 c1 cells did not grow at all (this is unexpected given that MDA-MB-231 cells generally grow very aggressively as xenograft tumors), whereas the MDA-MB-231 KO c1 cell tumors grew reasonably well. In contrast, both the MDA-MB-231 KO c2 and Rosa26 c2 cells grew poorly and with odd kinetics. The authors need to clearly acknowledge these imperfections in their own data and explain why the MDA-MB-231 cell results look so strange.

2\) The Sanger sequencing of the PCR product from the knockout clones as shown is not a very informative presentation of the data. It would be more rigorous to pick \~10 clones of the PCR product after topo cloning and sequence these to get a more accurate representation of the gRNA-mediated alterations. Are the alterations shown homozygous, heterozygous, or hemizygous?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Charles Sawyers (Senior Editor) and a Reviewing Editor.

The revised manuscript has been improved; however, the title, as written, implies that a new function of MELK has been revealed, and does not adequately describe the key conclusion. While the key conclusion is actually quite similar to that reflected in the title of your previous *eLife* article, it would be more appropriate to change the title to something along those lines.

10.7554/eLife.32838.057

Author response

> Essential revisions:
>
> 1\) Although the Cal51 xenograft data are reasonable, the MDA-MB-231 xenograft data in [Figure 2G](#fig2){ref-type="fig"} are simply not convincing The Rosa 26 c1 cells did not grow at all (this is unexpected given that MDA-MB-231 cells generally grow very aggressively as xenograft tumors), whereas the MDA-MB-231 KO c1 cell tumors grew reasonably well. In contrast, both the MDA-MB-231 KO c2 and Rosa26 c2 cells grew poorly and with odd kinetics. The authors need to clearly acknowledge these imperfections in their own data and explain why the MDA-MB-231 cell results look so strange.

MDA-MB-231 is a highly-heterogeneous breast cancer cell line. Sub-populations within MDA-MB-231 exhibit significant differences in gene expression, proliferation, and colony-formation ability. For instance, Khan et al., 2017, derived single-cell clones from 12 MDA-MB-231 cells, and observed striking differences in their growth rates. Sub-populations within MDA-MB-231 are also known to exhibit varying levels of "stem cell-like" or "tumor-initiating" behavior (Fillmore et al., 2008). We hypothesized that the poor growth of our MDA-MB-231 clones as xenografts could simply reflect the fact that cells in the parental population display different abilities to form tumors, and, by chance, we isolated several clones with limited tumor initiating capacity. To test this, we performed additional xenografts using non-clonally-derived MDA-MB-231 populations ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). For these experiments, we transduced the MDA-MB-231 parental population with a Rosa26 gRNA or two different gRNAs targeting MELK, and then selected gRNA-expressing cells without single-cell cloning. We verified by western blotting that the transduced cells exhibited near-complete depletion of MELK ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). When these cell populations were injected into nude mice, they grew significantly faster than our MDA-MB-231 clones grew, and the animals had to be sacrificed within 26 days after injection. Additionally, the MELK-depleted populations grew at comparable or superior rates to the control populations. These results suggest that the poor growth of our clonal xenografts is due to differences in tumor-formation potential between single cells from MDA-MB-231, and further verify that MELK is dispensable for breast cancer growth.

> 2\) The Sanger sequencing of the PCR product from the knockout clones as shown is not a very informative presentation of the data. It would be more rigorous to pick \~10 clones of the PCR product after topo cloning and sequence these to get a more accurate representation of the gRNA-mediated alterations. Are the alterations shown homozygous, heterozygous, or hemizygous?

We initially verified our A375 and DLD1 MELK-knockout clones by PCR-amplifying and sequencing the site targeted by the gRNA and by western blotting. As suggested by the reviewers, we further verified knockout status by using TOPO cloning to sequence individual MELK alleles from each clone ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In total, 58 of 58 alleles that we sequenced had mutations at the locus targeted by the guide RNA, verifying on-target CRISPR cutting. DLD1 is a diploid cancer cell line with two copies of MELK, and our sequencing indicated that one MELK-KO clone has a homozygous 10bp deletion in MELK, while the other clone has different indels in each allele.

A375 is an aneuploid cell line with three copies of MELK. Two findings from this clone are worth noting. First, in one clone, we recovered seven different indel mutations in the MELK gene. We hypothesize that at the time of single-cell sorting, one allele in this cell had acquired a small deletion that did not fully abolish gRNA recognition. Then, during clonal expansion, this allele underwent additional mutagenesis to generate the multiple large indels that we recovered. Secondly, in another A375 clone, we identified one allele that had three different single-nucleotide substitutions that generated three independent missense mutations (E15V, T16I, I17L). For our guide design, we followed the strategy of Shi and Vakoc (Nature Biotech, 2015), and chose gRNA sequences that target conserved, functional protein domains. The guide present in this clone targets the MELK ATP binding domain, likely explaining why these missense mutations are sufficient to destabilize the protein despite the lack of an indel.

To provide additional evidence that all of our MELK-knockout clones lack detectable MELK protein, we performed western blotting using a second antibody that recognizes a distinct MELK epitope. We observed no protein expression in any MELK-KO clone using antibodies that recognize either the MELK N-terminus or the MELK C-terminus ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In total, 100% of our topo-sequenced alleles harbor mutations in MELK, and western blotting with multiple antibodies failed to detect MELK, verifying that our MELK-KO clones lack wild-type MELK.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The revised manuscript has been improved; however, the title, as written, implies that a new function of MELK has been revealed, and does not adequately describe the key conclusion. While the key conclusion is actually quite similar to that reflected in the title of your previous eLife article, it would be more appropriate to change the title to something along those lines.

We have changed our manuscript\'s title to "MELK expression correlates with tumor mitotic activity but is not required for cancer growth".

[^1]: These authors contributed equally to this work.
